Table 3.
Univariate and multivariate analyses of covariates associated with progression-free survival in patients with metastatic NPC
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95 % CI) | P | HR (95 % CI) | P | |
| Age (<45 years vs. ≥45 years) | 1.01 (0.87–1.18) | 0.863 | 1.03 (0.88–1.20) | 0.760 |
| Sex (men vs. women) | 1.04 (0.85–1.27) | 0.730 | 1.04 (0.84–1.27) | 0.745 |
| UICC T category (T1–2 vs. T3–4) | 0.92 (0.79–1.07) | 0.289 | 0.92 (0.78–1.07) | 0.274 |
| UICC N category (N0–1 vs. N2–3) | 1.23 (1.05–1.43) | 0.009 | 1.29 (1.10–1.51) | 0.002 |
| Metastasis onset (synchronous vs. metachronous) | 1.04 (0.88–1.23) | 0.647 | 1.17 (0.98–1.39) | 0.091 |
| Solitary lesion (no vs. yes) | 0.69 (0.55–0.87) | 0.001 | 0.87 (0.68–1.12) | 0.281 |
| Lung metastasis (absent vs. present) | 0.87 (0.75–1.02) | 0.083 | 0.98 (0.76–1.27) | 0.900 |
| Liver metastasis (absent vs. present) | 1.50 (1.27–1.77) | <0.001 | 1.50 (1.19–1.90) | 0.001 |
| Bone metastasis (absent vs. present) | 1.27 (1.09–1.48) | 0.003 | 1.33 (1.05–1.68) | 0.019 |
| Number of involved sites (one vs. two or more) | 1.47 (1.25–1.72) | <0.001 | 1.08 (0.84–1.38) | 0.556 |
| Treatment modality (CT vs. CT + LT) | 0.68 (0.57–0.81) | <0.001 | 0.70 (0.58–0.85) | 0.001 |
| BMI | 0.139a | 0.407a | ||
| Underweight vs. normal weight | 0.87 (0.72–1.06) | 0.141 | 0.91 (0.75–1.11) | 0.367 |
| Underweight vs. overweight/obese | 0.80 (0.64–1.00) | 0.042 | 0.86 (0.68–1.08) | 0.181 |
UICC Union of International Cancer Control; CT chemotherapy; LT local therapy; BMI body mass index; HR hazard ratio; CI confidence interval
a P value with respect to the significance of differential prognosis between BMI subgroups